REMICADE: FDA advisory panel recommends approval of biosimilar Remicade

Feb 9 Reuters A medical advisory panel to the U.S. Food and Drug Administration on Tuesday recommended approval of a biosimilar form of Johnson & Johnson's Remicade arthritis drug deciding it was highly similar to the blockbuster branded product.